Market closedNon-fractional
Immunovant/IMVT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Immunovant
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Ticker
IMVT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
207
Website
immunovant.com
Immunovant Metrics
BasicAdvanced
$3.9B
Market cap
-
P/E ratio
-$1.88
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$3.9B
Beta
0.72
Financial strength
Current ratio
13.697
Quick ratio
13.184
Total debt to equity
0.022
Management effectiveness
Return on assets (TTM)
-31.50%
Return on equity (TTM)
-52.91%
Valuation
Price to book
6.26
Price to tangible book (TTM)
6.26
Price to free cash flow (TTM)
-17.07
Growth
Earnings per share change (TTM)
9.56%
3-year earnings per share growth
15.33%
What the Analysts think about Immunovant
Analyst Ratings
Majority rating from 15 analysts.
Immunovant Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$0
NaN%
Net income
-$75M
46.50%
Profit margin
0.00%
NaN%
Immunovant Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.57
-$0.45
-$0.36
-$0.52
-
Expected
-$0.45
-$0.47
-$0.43
-$0.43
-$0.52
Surprise
27.71%
-4.37%
-16.53%
21.88%
-
Immunovant News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunovant stock?
Immunovant (IMVT) has a market cap of $3.9B as of July 04, 2024.
What is the P/E ratio for Immunovant stock?
The price to earnings (P/E) ratio for Immunovant (IMVT) stock is 0 as of July 04, 2024.
Does Immunovant stock pay dividends?
No, Immunovant (IMVT) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Immunovant dividend payment date?
Immunovant (IMVT) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunovant?
Immunovant (IMVT) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Immunovant stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.